AnGes, Inc. is a biopharmaceutical company with a mission to provide patients suffering from diseases for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on development of gene medicines, a next-generation biopharmaceutical.

SBI Pharmaceuticals transferred the laboratory from KOBE to iCONM in KAWASAKI in March, 2018 as the core of the Research & Development. The laboratory is conducting advanced and creative R&D, aiming to utilize 5-ALA in the fields of Medicine, Cosmetics and Health foods.

Our mission is to strive for the wholehearted satisfaction and enrichment of the lives of people globally and to contribute to the sustainability of the world, with products and brands of excellent value that are created from the consumer's and customer's perspective.

We work as a reliable public experimental and research institute, by means of supporting creation of innovation and promoting local industry, science and technology.

Our goal is to create a needleless society in medicine using our Transdermal Delivery System research. We aim to contribute to medical innovation by taking on treatments which were considered challenging such as in-home cancer treatments, retinal treatment via ophthalmic solution, topical vaccines and treatments for eczemas which drastically lower one’s quality of life.

Taking advantage of the clinical development experience worldwide in nanomicelle-type pharmaceutical, in collaboration with the National Cancer Research Center, we are challenging to research and develop novel antibody-conjugated nanomachines to establish the therapies targeting refractory cancer such as brain tumor where urgent medical needs exist.

NOF Group pursues multi-faceted business in a broad spectrum from biosphere to outer space as a chemical manufacturer. As a corporate group that develops and provides functional materials that contribute to prosperity, NOF CORPORATION will grow by investing our corporate resources.

Nittobo NI-Tech
We have opened NI-Tech laboratory with a view to conducting collaborative research with academic institutions both at home and abroad to create unique diagnostic technologies and solutions and to bolster research capacity and capability of the Medical Division.

Under existing BBB, it inhibits the delivery of many drugs into the brain thus preventing sufficient therapeutics effects. We aim to commercialize the technology for crossing BBB via Glucose transporter 1 by glycosylated Nanomachine including a drug.

Metcela is a clinical stage biotech startup in Japan, developing an innovative cell therapy for heart failure using a specific population of fibroblasts found in the heart, called “VCFs” or VCAM-1-positive cardiac fibroblasts.

AccuRna, Inc. is a biotech startup engaged in R&D with its unique DDS technologies striving for discovery of new nucleic acid medicines for currently intractable diseases.

Since its founding in 1894, Kowa Group has grown with more than a 100-year history. The Kowa Group, which has its bases and markets at home and abroad as a conglomerate enterprise compounded of manufacturers and trading company, has developed activities in various business fields. In the pharmaceutical division, we research, develop and manufacture OTC drugs, life support products, dietary supplements, drink, medical device and ethical drugs to contribute to your better health and more comfortable life.

Under Construction